PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.

Abstract Chemotherapy with trastuzumab, pertuzumab and docetaxel (TPD regimen) is now strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER)2-positive breast cancer. In this study, we analyzed the expression of HER 1-4 proteins, and investigated whether or not their expression was predictive of the response of advanced HER2-positive breast cancer to chemotherapy with the TPD regimen.
PMID
Related Publications

Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Authors

Mayor MeshTerms
Keywords

HER2

HER3

Pertuzumab

breast cancer

trastuzumab

Journal Title anticancer research
Publication Year Start




PMID- 29599351
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy 
      with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast
      Cancer.
PG  - 2285-2294
AB  - BACKGROUND: Chemotherapy with trastuzumab, pertuzumab and docetaxel (TPD regimen)
      is now strongly recommended as a treatment option for first-line therapy for
      advanced human epidermal growth factor receptor (HER)2-positive breast cancer. In
      this study, we analyzed the expression of HER 1-4 proteins, and investigated
      whether or not their expression was predictive of the response of advanced
      HER2-positive breast cancer to chemotherapy with the TPD regimen. PATIENTS AND
      METHODS: The study consisted of 29 cases in which TPD regimen chemotherapy was
      carried out from September 2013 to November 2015. The expression levels of
      estrogen receptor (ER), progesterone receptor (PgR), Ki67, HER1, HER2, HER3 and
      HER4 were evaluated using immunostaining employing needle biopsy specimens.
      RESULTS: The overall response rate (ORR) was significantly higher in the
      HER3-positive group than in the HER3-negative group (p=0.002). In prognostic
      analysis, the HER3-positive group showed a significant progression-free survival 
      extension over the HER3-negative group (p=0.042, log-rank). In univariate
      analysis, objective response (p=0.004, hazard ratio(HR)=0.123) and positive HER3 
      expression (p=0.023, HR=0.279) significantly contributed to extension of
      progression-free survival interval. CONCLUSION: HER3 expression may be a useful
      factor for predicting the response of HER2-positive breast cancer to chemotherapy
      with the TPD regimen.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Takada, Koji
AU  - Takada K
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Kashiwagi, Shinichiro
AU  - Kashiwagi S
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan [email protected]
FAU - Goto, Wataru
AU  - Goto W
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Asano, Yuka
AU  - Asano Y
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Morisaki, Tamami
AU  - Morisaki T
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Fujita, Hisakazu
AU  - Fujita H
AD  - Department of Scientific and Linguistic Fundamentals of Nursing, Osaka City
      University Graduate School of Nursing, Osaka, Japan.
FAU - Takashima, Tsutomu
AU  - Takashima T
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Ohsawa, Masahiko
AU  - Ohsawa M
AD  - Department of Diagnostic Pathology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Hirakawa, Kosei
AU  - Hirakawa K
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Ohira, Masaichi
AU  - Ohira M
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (docetaxel)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (ERBB3 protein, human)
RN  - EC 2.7.10.1 (ERBB4 protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-3)
RN  - EC 2.7.10.1 (Receptor, ErbB-4)
RN  - K16AIQ8CTM (pertuzumab)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Pharmacological/*analysis/metabolism
MH  - Biomarkers, Tumor/analysis/metabolism
MH  - Breast Neoplasms/diagnosis/*drug therapy/metabolism/pathology
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Multigene Family
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Receptor, Epidermal Growth Factor/metabolism
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptor, ErbB-3/metabolism
MH  - Receptor, ErbB-4/metabolism
MH  - Taxoids/*administration & dosage
MH  - Trastuzumab/*administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *HER2
OT  - *HER3
OT  - *Pertuzumab
OT  - *breast cancer
OT  - *trastuzumab
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/01/09 00:00 [received]
PHST- 2018/02/05 00:00 [revised]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2285 [pii]
AID - 10.21873/anticanres.12473 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2285-2294. doi: 10.21873/anticanres.12473.